Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2017
18th World Conference on Lung Cancer
Access to all presentations that occur during the 18th World Conference on Lung Cancer in Yokohama, Japan
Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Download PDF of the Conference Program: Click Here.
Presentations will be available 24 hours after their live presentation time
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
-
+
P2.02 - Biology/Pathology
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 75
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.02-001 - Detection of Gene Fusions in NSCLC Using NGS Fusion Assay
09:30 - 09:30 | Presenter: Yoon-La Choi
- Abstract
Loading... -
+
P2.02-002 - Digital Multiplexed Detection of Single Nucleotide Variants (SNV) in Non-Small Cell Lung Cancer Using NanoString Technology
09:30 - 09:30 | Presenter: Brielle Parris
- Abstract
Loading... -
+
P2.02-003 - A Practical Prognostic lncRNA Signature for Lung Squamous Cell Carcinoma
09:30 - 09:30 | Presenter: Xiaoshun Shi
- Abstract
Loading... -
+
P2.02-004 - Gene Mutational Feature in Lung Enteric Adenocarcinoma by the Next Generation Sequencing
09:30 - 09:30 | Author(s): W. Wang
- Abstract
Loading... -
+
P2.02-005 - 13 Cases of Molecular Features Analysis in Pulmonary Mucoepidermoid Carcinoma
09:30 - 09:30 | Author(s): Chunwei Xu
- Abstract
Loading... -
+
P2.02-006 - NovoSV: Identify and Parse the Pattern of Chromosomal Structural Variation
09:30 - 09:30 | Author(s): Chunwei Xu
- Abstract
Loading... -
+
P2.02-007 - Molecular Spectrum of STK11 Gene Mutations in Patients with Non-Small-Cell Lung Cancer in Chinese Patients
09:30 - 09:30 | Author(s): X. Chen
- Abstract
Loading... -
+
P2.02-008 - Snai1-Expression Cancer-Associated Fibroblast Induce Epithelial-Mesenchymal Transition of Lungcancer Cells through miR-33b
09:30 - 09:30 | Author(s): J. You
- Abstract
Loading... -
+
P2.02-009 - Metabolomic Analysis in Lung Cancer
09:30 - 09:30 | Presenter: Naohiro Kajiwara
- Abstract
Loading... -
+
P2.02-010 - Oncogenic Role of PKP1 in Non-Small-Cell Lung Cancer.
09:30 - 09:30 | Author(s): J. Martin-Padron
- Abstract
Loading... -
+
P2.02-011 - Clinical and Molecular Features of Lung Cancers with Increased FGFR1 mRNA and/or Gene Copy Number
09:30 - 09:30 | Presenter: Terry L. Ng
- Abstract
Loading... -
+
P2.02-012 - The Epigenetic Role of LSD1+8a in Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Aditya Wirawan
- Abstract
Loading... -
+
P2.02-013 - Investigation of Genomic and TCR Repertoire Evolution of AAH, AIS, MIA to Invasive Lung Adenocarcinoma by Multiregion Exome and TCR Sequencing
09:30 - 09:30 | Author(s): X. Hu
- Abstract
Loading... -
+
P2.02-014 - Simultaneous Gene Profiling of Advanced NSCLC: Single-Molecule Quantification of DNA and RNA by nCounter3D™ Technology
09:30 - 09:30 | Presenter: Cristina Teixidó
- Abstract
Loading... -
+
P2.02-015 - Mutation Patterns in a Swedish Non-Small Cell Lung Cancer Cohort
09:30 - 09:30 | Presenter: Linnea La Fleur
- Abstract
Loading... -
+
P2.02-016 - Pulmonary Sarcomas: A Comprehensive Genomic Profiling Study
09:30 - 09:30 | Presenter: Jeffrey S. Ross
- Abstract
Loading... -
+
P2.02-017 - Aberrant Expression of Long Non-Coding RNAs from Pseudogene Loci Highlights Alternative Mechanisms of Cancer Gene Regulation
09:30 - 09:30 | Presenter: Greg L. Stewart
- Abstract
Loading... -
+
P2.02-018 - Genomic Profiling of Driver Gene Mutations in 498 Chinese NSCLC Patients
09:30 - 09:30 | Presenter: Minghui Wang
- Abstract
Loading... -
+
P2.02-019 - Utility of Circulating Tumor DNA (CtDNA) in Prognostication of Lung Cancer vs. Other Cancer Types
09:30 - 09:30 | Presenter: Francisco III Maramara Heralde
- Abstract
Loading... -
+
P2.02-020 - Molecular Characteristics of Patients with PTEN Mutations in Chinese Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): Xiaobing Zheng
- Abstract
Loading... -
+
P2.02-021 - Prevalence of PTPRD Gene Mutations in Chinese Non-Small Cell Lung Cancer Patients
09:30 - 09:30 | Author(s): S. Wang
- Abstract
Loading... -
+
P2.02-022 - Alternative Regulation of Cancer-Associated Genes through Modulation of Long Non-Coding RNAs
09:30 - 09:30 | Presenter: Adam Patrick Sage
- Abstract
Loading... -
+
P2.02-023 - Targeted Gene Expression Profiling to Evaluate Minimal Diagnostic FFPE-Biopsies from NSCLC-Patients
09:30 - 09:30 | Presenter: Johanna Sofia Margareta Mattsson
- Abstract
Loading... -
+
P2.02-024 - False Positivity Due to Polysomy in Fluorescence in Situ Hybridization
09:30 - 09:30 | Author(s): A.L. Görtz
- Abstract
Loading... -
+
P2.02-025 - Histological Difference of Tumor-Infiltrate Lymphocytes in Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Naohiro Kobayashi
- Abstract
Loading... -
+
P2.02-026 - Impact of PD-L1 Expression on 18F-FDG-PET in Pulmonary Squamous Cell Carcinoma
09:30 - 09:30 | Presenter: Norimitsu Kasahara
- Abstract
Loading... -
+
P2.02-027 - Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)?
09:30 - 09:30 | Author(s): J. Rogado
- Abstract
Loading... -
+
P2.02-028 - Prognostic Value of Cox-2 Expression Differs Depending on CD8+ T Lymphocytes and PD-L1 Expression in Resected Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Katsuhiko Shimizu
- Abstract
Loading... -
+
P2.02-029 - Morphologic Features of Lung Adenocarcinoma Expressing PD-L1 Protein in Small Biopsy Specimens
09:30 - 09:30 | Presenter: Eun Su Park
- Abstract
Loading... -
+
P2.02-030 - Bavituximab in Combination With Nivolumab Enhances Tumor Immune Response in a 3D Ex Vivo System of Lung Cancer Patients
09:30 - 09:30 | Author(s): M. Mediavilla-Varela
- Abstract
Loading... -
+
P2.02-031 - Relationship between PD-L1 Expression and EGFR/HER2 Signaling in Non-Small-Cell Lung Cancer
09:30 - 09:30 | Presenter: Riki Okita
- Abstract
Loading... -
+
P2.02-032 - Interplaying between Gamma-H2AX and Autophagy in A549 Cells Treated with Cisplatin and Etoposide
09:30 - 09:30 | Presenter: Jong Wook Shin
- Abstract
Loading... -
+
P2.02-033 - The Association of PD-L1 Expression with Clinical Characteristics and EGFR and ALK Status in Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Jinghui Wang
- Abstract
Loading... -
+
P2.02-034 - PD-L1 Expression Can Be a Prognostic Marker in EGFR Mutant NSCLC Patients Treated with Erlotinib
09:30 - 09:30 | Presenter: Niki Karachaliou
- Abstract
Loading... -
+
P2.02-035 - PD-L1 IHC Test on Cytological Cell Block Specimen; Potential Utility and Practical Issues
09:30 - 09:30 | Presenter: Michiko Sugiyama
- Abstract
Loading... -
+
P2.02-036 - The Expression Pattern of CD26/DPP4 in Human Lung Cancer
09:30 - 09:30 | Author(s): J. Jang
- Abstract
Loading... -
+
P2.02-037 - CD14+ Cell Tumor Microenvironment Infiltration Correlates with Poor Overall Survival in Patients with Early Stage Lung Cancer
09:30 - 09:30 | Presenter: Erin Schenk
- Abstract
Loading... -
+
P2.02-038 - Imaging Platform for the Quantification of Cell-Cell Spatial Organization within the Tumour-Immune Microenvironment
09:30 - 09:30 | Presenter: Katey S.S. Enfield
- Abstract
Loading... -
+
P2.02-039 - Spatial Heterogeneity of Immunological Markers Between Cores and Complete NSCLC Sections Using Multispectral Fluorescent IHC
09:30 - 09:30 | Presenter: Geoffrey Peters
- Abstract
Loading... -
+
P2.02-040 - Cytology Cell Block Is Suitable for Immunohistochemical Testing for PD-L1 in Lung Cancer
09:30 - 09:30 | Presenter: Hangjun Wang
- Abstract
Loading... -
+
P2.02-041 - Update on Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer (ICON Project)
09:30 - 09:30 | Presenter: Jianjun Zhang
- Abstract
Loading... -
+
P2.02-042 - Clinical Significance of the Tumor Expression of PD-L1 Using Four Immunohistochemistry Assays in Non-Small Cell Lung Cancer. Multicentre Study
09:30 - 09:30 | Presenter: Cristian Ortiz -Villalón
- Abstract
Loading... -
+
P2.02-043 - Multicentre Assessment of PD-L1 Immunohistochemistry: Challenges for Establishing the Concordance Between Four Different Antibodies
09:30 - 09:30 | Presenter: Cristian Ortiz -Villalón
- Abstract
Loading... -
+
P2.02-044 - Pulmonary Findings in 7 Autopsy Cases of Patients Treated with Immune Checkpoint Inhibitors
09:30 - 09:30 | Author(s): E.D. Thompson
- Abstract
Loading... -
+
P2.02-045 - PD-L1 Assessment in Cytology Samples
09:30 - 09:30 | Author(s): A. Lerner
- Abstract
Loading... -
+
P2.02-046 - Assessment of PDL1 and Immunoprofiling Using Multiplex Quantitative Immunofluorescence in Lung Cancer: Clinical Implications
09:30 - 09:30 | Author(s): Tabatha Gutierrez Prieto
- Abstract
Loading... -
+
P2.02-047 - Comparison of PD-L1 Immunohistochemistry Assays and Response to PD-L1 Inhibitors
09:30 - 09:30 | Presenter: Sanja Dacic
- Abstract
Loading... -
+
P2.02-048 - Survival Correlation Between TP53 Gene and PD-L1 Tumour Expression in Resected Non-Small Cell Lung Carcinoma
09:30 - 09:30 | Presenter: Jane Sze Yin Sui
- Abstract
Loading... -
+
P2.02-049 - Immunohistochemical Approach in Predicting Primary Lung Cancer Outcome: A Single Center Study
09:30 - 09:30 | Presenter: Gulrukh Komiljonovna Botiralieva
- Abstract
Loading... -
+
P2.02-050 - Weighted Genes Co-expression Network Analysis of Lung Cancers Concerning Patients Overall Survival and Cancer Stage
09:30 - 09:30 | Presenter: Haolong Qi
- Abstract
Loading... -
+
P2.02-051 - Bevacizumab Prevents Growth of Established Non-Small Cell Lung Cancer Brain Metastases in Hematogenous Brain Metastasis Model
09:30 - 09:30 | Presenter: Chinami Masuda
- Abstract
Loading... -
+
P2.02-052 - A Clinically-Validated Universal Companion Diagnostic Platform for Cancer Patient Care
09:30 - 09:30 | Presenter: James Sun
- Abstract
Loading... -
+
P2.02-053 - The Prognostic Value of 18 Circulating Markers of Inflammation, Endothelial Activation and
Extracellular Matrix Remodelling in Non-small Cell Lung Cancer Patients09:30 - 09:30 | Presenter: Janna Berg
- Abstract
Loading... -
+
P2.02-054 - Thymidylate Synthase Promotes Epithelial-To-Mesenchymal Transition and Aggressiveness in NSCLC
09:30 - 09:30 | Presenter: Paolo Ceppi
- Abstract
Loading... -
+
P2.02-055 - Stratifin Regulates Stabilization of Receptor Tyrosine Kinases via Activation of Ubiquitin-Specific Protease 8 in Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Aya Shiba
- Abstract
Loading... -
+
P2.02-056 - Regulatory Variants in Cancer-Related Pathway Genes Predict Survival of Patients with Surgically Resected Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Eungbae Lee
- Abstract
Loading... -
+
P2.02-057 - Expression of MGAT4a and MGAT5 Are Correlated with Poorer Outcome in Advanced Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Yoko Nakanishi
- Abstract
Loading... -
+
P2.02-058 - Endogenous Arginase 2 as a Biomarker for PEGylated Arginase 1 Treatment in Squamous Cell Lung Carcinoma Xenograft Models
09:30 - 09:30 | Presenter: Sze Kwan Lam
- Abstract
Loading... -
+
P2.02-059 - Genomic Mutation Patterns Detected with Cancer Panel Can Predict Postoperative Prognosis in Clinical Stage I Adenocarcinoma
09:30 - 09:30 | Presenter: Kwanyong Hyun
- Abstract
Loading... -
+
P2.02-060 - Prognostic Significance of EDIL3 Expression and Correlation with Mesenchymal Phenotype and Microvessel Density in Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Young Wha Koh
- Abstract
Loading... -
+
P2.02-061 - Two Novel Protein-Based Prognostic Signatures Improve Risk Stratification of Early Lung ADC and SCC Patients
09:30 - 09:30 | Author(s): E. Martinez-Terroba
- Abstract
Loading... -
+
P2.02-062 - The MicroRNAs Associated with Recurrence and Metastasis of Stage I Lung Adenocarcinoma
09:30 - 09:30 | Author(s): H. Dai
- Abstract
Loading... -
+
P2.02-063 - Oncogenic microRNAs Associated with Poor Prognosis Are Up-Regulated on the Amplicon in Squamous Cell Lung Carcinoma
09:30 - 09:30 | Presenter: Sana Yokoi
- Abstract
Loading... -
+
P2.02-064 - A Novel 5-miR Signature Shows Potential as a Diagnostic Tool and as a Predictive Biomarker of Cisplatin Response in NSCLC
09:30 - 09:30 | Author(s): L. Mac Donagh
- Abstract
Loading... -
+
P2.02-065 - RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors
09:30 - 09:30 | Presenter: Anna Tessari
- Abstract
Loading... -
+
P2.02-066 - Identification of Crucial Gene Targets in the in Situ Environment of Cancer by Google Network Ranking
09:30 - 09:30 | Presenter: Victor Pontén
- Abstract
Loading... -
+
P2.02-067 - LKB1 Loss Is Associated with DNA Hypomethylation in Human Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Michael John Koenig
- Abstract
Loading... -
+
P2.02-068 - BRG1 and p53 Expression in Resected Stage I – III Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): A.A. Elegbede
- Abstract
Loading... -
+
P2.02-069 - Targeting Neuropilin-1 in NSCLC
09:30 - 09:30 | Presenter: Martin P Barr
- Abstract
Loading... -
+
P2.02-070 - C-MET as a Biomarker in Patients with Surgically Resected Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Georgios Tsakonas
- Abstract
Loading... -
+
P2.02-071 - Prospective Molecular Study of 22 Genes by NGS in Patients with Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Single Institution Experience
09:30 - 09:30 | Presenter: Valeria Cecilia Denninghoff
- Abstract
Loading... -
+
P2.02-072 - Reliability of Small Biopsy Samples for Tumor PD-L1 Expression in Non-Small-Cell Lung Cancer
09:30 - 09:30 | Presenter: Akihito Tsunoda
- Abstract
Loading... -
+
P2.02-073 - Cytoplasmic Mislocalization of ECT2 Protein Is Associated with Poor Prognosis in Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Zeinab Kosibaty
- Abstract
Loading... -
+
P2.02-073a - Does the PD-L1 Status and TIL Intensity Change in NSCLC and Syncronous Brain Metastases?
09:30 - 09:30 | Presenter: Buge Oz
- Abstract
Loading... -
+
P2.02-073b - Genetic Profile in NSCLC Biopsy Samples. A Muticenter Local Study
09:30 - 09:30 | Presenter: Norma Pilnik
- Abstract
Loading...
-
+
P2.03 - Chemotherapy/Targeted Therapy
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 59
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.03-001 - Survivors and Adverse Events After First-Line Target Therapy for Advanced Non-Small Cell Lung Cancer Patients in Taiwan
09:30 - 09:30 | Presenter: Lin Zhi Xuan
- Abstract
Loading... -
+
P2.03-002 - Impact of EGFR-Tyrosine Kinase Inhibitors for Postoperative Recurrent Non-Small Cell Lung Cancer Harboring EGFR Mutations
09:30 - 09:30 | Presenter: Satoshi Igawa
- Abstract
Loading... -
+
P2.03-003 - Cost Effectiveness of Gefitinib for Lung Adenocarcinoma Patients with Mutant Epidermal Growth Factor Receptor
09:30 - 09:30 | Author(s): T. Hsia
- Abstract
Loading... -
+
P2.03-004 - Recurrent Response to Advanced NSCLC with Erlotinib Developing Central Nervous System Failure during Gefitinib or Icotinib Treatment
09:30 - 09:30 | Presenter: Di Ma
- Abstract
Loading... -
+
P2.03-005 - Overall Survival Results from a Prospective, Multicenter Phase II Trial of Low-Dose Erlotinib as Maintenance in NSCLC Harboring EGFR Mutation
09:30 - 09:30 | Presenter: Satoshi Hirano
- Abstract
Loading... -
+
P2.03-006 - How Many Years of Life Have We Lost in Brazil Due to the Lack of Access to Anti-EGFR TKIs in the National Public Health System?
09:30 - 09:30 | Presenter: Pedro Aguiar Jr
- Abstract
Loading... -
+
P2.03-007 - Loxoprofen Prevents EGFR-TKI-Related Skin Rash in Non-Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
09:30 - 09:30 | Presenter: Yohei Iimura
- Abstract
Loading... -
+
P2.03-008 - Phase I/II Study of Intermitted Erlotinib in Combination with Docetaxel in Patients with Recurrent NSCLC with Wild-Type EGFR: WJOG 4708L
09:30 - 09:30 | Presenter: Tatsuo Kimura
- Abstract
Loading... -
+
P2.03-009 - Clarification of Mechanisms of Acquired Resistance for Afatinib Using Plasma Samples
09:30 - 09:30 | Presenter: Tomomi Nakamura
- Abstract
Loading... -
+
P2.03-010 - Updated Survival Outcomes of NEJ005/TCOG0902, a Randomized PII of Gefitinib and Chemotherapy in EGFR-Mutant NSCLC
09:30 - 09:30 | Presenter: Tatsuro Fukuhara
- Abstract
Loading... -
+
P2.03-011 - Correlation and Problems of Re-Biopsy and Liquid Biopsy for Detecting T790M Mutation
09:30 - 09:30 | Presenter: Kazutoshi Komiya
- Abstract
Loading... -
+
P2.03-012 - Characterization of the Efficacies of Osimertinib and Nazartinib against Cells Expressing Epidermal Growth Factor Receptor Mutations
09:30 - 09:30 | Presenter: Keita Masuzawa
- Abstract
Loading... -
+
P2.03-013 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
09:30 - 09:30 | Author(s): K. Chen
- Abstract
Loading... -
+
P2.03-014 - A Phase I Study of Afatinib for Patients Aged 75 or Older with Advanced NSCLC Harboring EGFR Mutations
09:30 - 09:30 | Author(s): K. Baba
- Abstract
Loading... -
+
P2.03-015 - Efficacy of EGFR-TKIs for EGFR Mutatnt NSCLC Patients with Central Nervous System Metastases: A Retrospective Analysis
09:30 - 09:30 | Presenter: Kenichi Koyama
- Abstract
Loading... -
+
P2.03-016 - Clinical Utility of Liquid Biopsy for Detecting EGFR T790M Mutation Is Very Limited
09:30 - 09:30 | Presenter: Tomohiro Sakamoto
- Abstract
Loading... -
+
P2.03-017 - Clinical Features and Treatment with Afatinib in Patients with Squamous Cell Lung Cancer with Sensitive EGFR Mutations
09:30 - 09:30 | Presenter: Yuri Taniguchi
- Abstract
Loading... -
+
P2.03-018 - Diagnostic Yield of Fine-Needle Aspiration and Core-Needle Biopsy in Assessment of EGFR and ALK Mutation Status in Non–Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Junghoon Kim
- Abstract
Loading... -
+
P2.03-019 - Sizing Capillary Electrophoresis with PCR to Detect Various EGFR Exon 19 Deletions in Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Eiji Nakajima
- Abstract
Loading... -
+
P2.03-020 - Pemetrexed Continuation Maintenance versus Conventional Platinum-based Doublet Chemotherapy in EGFR-negative Lung Adenocarcinoma: Retrospective Analysis
09:30 - 09:30 | Author(s): I.K. Hwang
- Abstract
Loading... -
+
P2.03-021 - A Phase I Study Evaluating the Combination of Afatinib, Carboplatin and Pemetrexed after Failure of 1St Generation EGFR-TKIs
09:30 - 09:30 | Presenter: Ou Yamaguchi
- Abstract
Loading... -
+
P2.03-022 - Impact of EGFR Mutation on Clinical Outcome of Nintedanib plus Docetaxel in Previously Treated Non- Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): S. Hong
- Abstract
Loading... -
+
P2.03-023 - Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic
09:30 - 09:30 | Presenter: Jana Skrickova
- Abstract
Loading... -
+
P2.03-024 - Phase II Trial of AZD9291 in Second-Line Treatment after Acquired Resistance with T790M Mutation Detected From Circulating Tumor DNA
09:30 - 09:30 | Presenter: Young-Chul Kim
- Abstract
Loading... -
+
P2.03-025 - Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib
09:30 - 09:30 | Presenter: Maximilian Johannes Hochmair
- Abstract
Loading... -
+
P2.03-026 - Managing EGFR T790M Mutation in Advanced Non-Small Cell Lung Cancers in THAILAND
09:30 - 09:30 | Presenter: Thongbliew - Prempree
- Abstract
Loading... -
+
P2.03-027 - Comparative Longitudinal Toxicity Analysis of EGFR Mutated NSCLC Treated with Either Pemetrexed Carboplatin or Gefitinib
09:30 - 09:30 | Presenter: Mansi Sharma
- Abstract
Loading... -
+
P2.03-028 - Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial
09:30 - 09:30 | Presenter: Yuankai Shi
- Abstract
Loading... -
+
P2.03-029 - A Case of a Patient Harboring an EGFR Insertion of Exon 20 and Long Lasting Clinical Response to Afatinib
09:30 - 09:30 | Author(s): V. Lorandi
- Abstract
Loading... -
+
P2.03-030 - Cumulative Smoking Dose Affects the Clinical Outcomes of EGFR-Mutated Lung Adenocarcinoma Patients Treated with EGFR-TKIs
09:30 - 09:30 | Presenter: In Ae Kim
- Abstract
Loading... -
+
P2.03-031 - Efficacy of Gefitinib and Radiotherapy Combination in Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Elisna Syahruddin
- Abstract
Loading... -
+
P2.03-032 - Efficacy and Safety of Osimertinib as Third-Line or Later Therapy for T790M-Positive Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Hiroyuki Shimada
- Abstract
Loading... -
+
P2.03-033 - Propensity Score-Adjusted Survival Analysis of Non-Small Cell Lung Cancer Patients with Acquired Resistance to EGFR-TKI
09:30 - 09:30 | Presenter: Sho Watanabe
- Abstract
Loading... -
+
P2.03-034 - EGFR Exon 19 Deletion Is Associated with Favorable Overall Survival After First-Line Icotinib Therapy in Advanced NSCLC Patients
09:30 - 09:30 | Author(s): C. Zhang
- Abstract
Loading... -
+
P2.03-035 - Osimertinib in Relapsed EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases: Results from the TREM-Study
09:30 - 09:30 | Presenter: Inger Johanne Zwicky Eide
- Abstract
Loading... -
+
P2.03-036 - Comparing the Efficacy/Toxicity of Osimertinib and First Line EGFR-TKI by Individual Patient Analysis
09:30 - 09:30 | Presenter: Shoko Narita
- Abstract
Loading... -
+
P2.03-037 - Osimertinib in Relapsed EGFR-Mutated, T790M-Negative Non-Small Cell Lung Cancer (NSCLC) Patients: Results from the TREM-Study
09:30 - 09:30 | Presenter: Inger Johanne Zwicky Eide
- Abstract
Loading... -
+
P2.03-038 - Early Serum Tumor Markers After 14 Days of Tyrosine Kinase Inhibitor Target Therapy Predicts Outcomes in Patients with Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Kuo-Yang Huang
- Abstract
Loading... -
+
P2.03-039 - Compassionate Use of Osimertinib: Argentine Experience
09:30 - 09:30 | Presenter: Jose Nicolas Minatta
- Abstract
Loading... -
+
P2.03-040 - EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients
09:30 - 09:30 | Presenter: Chenguang Li
- Abstract
Loading... -
+
P2.03-041 - The Concentration of Avitinib in Cerebrospinal Fluid and Its Efficacy and Safety in NSCLC Patients with T790M Mutation
09:30 - 09:30 | Presenter: Hanping Wang
- Abstract
Loading... -
+
P2.03-042 - EGFR Mutation and Erlotinib Efficacy in Turkish Oncoregistry
09:30 - 09:30 | Presenter: Mahmut Gumus
- Abstract
Loading... -
+
P2.03-043 - A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naïve EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Sukhmani Kaur Padda
- Abstract
Loading... -
+
P2.03-044 - OSCILLATE - Phase 2 Trial of Alternating Osimertinib with Gefitinib in Patients with EGFR-T790M Mutation Positive Advanced NSCLC
09:30 - 09:30 | Presenter: Ben J Solomon
- Abstract
Loading... -
+
P2.03-045 - Updated Results of Phase II, Liquid Biopsy Study in EGFR Mutated NSCLC Patients Treated with Afatinib (WJOG 8114LTR)
09:30 - 09:30 | Presenter: Hidetoshi Hayashi
- Abstract
Loading... -
+
P2.03-046 - Lymhocyte-To-Monocyte Ratio and Mean Platelet Volume as Prognostic Factor in EGFR Mutant NSCLC Treated with EGFR TKI
09:30 - 09:30 | Presenter: Kousuke Watanabe
- Abstract
Loading... -
+
P2.03-047 - The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancer
09:30 - 09:30 | Presenter: Songtao Xu
- Abstract
Loading... -
+
P2.03-048 - Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
09:30 - 09:30 | Presenter: Yuki Shinno
- Abstract
Loading... -
+
P2.03-049 - Pulmonary Adenoid Cystic Carcinoma with EGFR Activating Mutation and Responds Well with Tyrosine Kinase Inhibitor
09:30 - 09:30 | Presenter: Jamal Zaini
- Abstract
Loading... -
+
P2.03-050 - The Efficacy of EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer Harboring G719X Mutation
09:30 - 09:30 | Presenter: Hanping Wang
- Abstract
Loading... -
+
P2.03-051 - The Impact of EGFR Mutations. Treatment with ITKs in Non Small Cell Lung Cancer Patients
09:30 - 09:30 | Presenter: Teresa García Manrique
- Abstract
Loading... -
+
P2.03-052 - Local Ablative Therapy for Oligoprogressive, EGFR-Mutant, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib
09:30 - 09:30 | Author(s): C. Kim
- Abstract
Loading... -
+
P2.03-053 - A Five-Year Audit of EGFR and ALK Testing at a Tertiary Care Centre in North India: More Sensitive Methods Do Make a Difference!
09:30 - 09:30 | Presenter: Valliappan Muthu
- Abstract
Loading... -
+
P2.03-054 - EGFR Mutation with Acquired C-MET Positive Reveals Potential Immunotherapeutic Vulnerabilities
09:30 - 09:30 | Presenter: Shan Su
- Abstract
Loading... -
+
P2.03-055 - Comparison of Afatinib Versus Erlotinib for Advanced Non-Small-Cell Lung Cancer Patients with Resistance to EGFR-TKI
09:30 - 09:30 | Presenter: Yuichi Sakamori
- Abstract
Loading... -
+
P2.03-056 - Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 in Slovakian NSCLC Patients - Updated Survival Data
09:30 - 09:30 | Presenter: Peter Berzinec
- Abstract
Loading... -
+
P2.03-057 - Effectiveness of Icotinib on Uncommon EGFR Exon 20 Insert Mutations: A763_Y 764insFQEA in Non-Small-Cell Lung Cancer
09:30 - 09:30 | Author(s): Chunwei Xu
- Abstract
Loading... -
+
P2.03-058 - Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Presenter: James Chih-Hsin Yang
- Abstract
Loading... -
+
P2.03-058a - T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive NSCLC
09:30 - 09:30 | Presenter: Takeshi Yoshida
- Abstract
No abstract available for this presentation
-
+
P2.04 - Clinical Design, Statistics and Clinical Trials
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 14
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.04-001 - BALTIC: A Phase 2, Open-Label Study of Novel Combinations of Immunotherapies or DDR Inhibitors in Platinum-Refractory ED-SCLC
09:30 - 09:30 | Presenter: Ihor Vynnychenko
- Abstract
Loading... -
+
P2.04-002 - CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
09:30 - 09:30 | Presenter: Luis Paz-Ares
- Abstract
Loading... -
+
P2.04-003 - Phase II Trial of X-396 (Ensartinib) for Chinese Patients with ALK (+) Non–Small-Cell Lung Cancer Who Progressed on Crizotinib
09:30 - 09:30 | Presenter: Li Zhang
- Abstract
Loading... -
+
P2.04-004 - IMpower010: A Phase III Study of Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Completely Resected NSCLC
09:30 - 09:30 | Presenter: Enriqueta Felip
- Abstract
Loading... -
+
P2.04-005 - GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC
09:30 - 09:30 | Presenter: Jürgen Wolf
- Abstract
Loading... -
+
P2.04-006 - ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection
09:30 - 09:30 | Presenter: Roy S. Herbst
- Abstract
Loading... -
+
P2.04-007 - KEYNOTE-604: Phase 3 Randomized, Double-Blind Trial of Pembrolizumab/Placebo plus Etoposide/Platinum for Extensive Stage-SCLC
09:30 - 09:30 | Presenter: Charles M Rudin
- Abstract
Loading... -
+
P2.04-008 - ATLANTIS: Phase III Study of PM01183 with Doxorubicin vs. CAV or Topotecan in Small-Cell Lung Cancer After Platinum Therapy
09:30 - 09:30 | Author(s): A. Farago
- Abstract
Loading... -
+
P2.04-009 - Randomized, Single-Blind Phase 1 Study of Pharmacokinetic Equivalence of ABP 215 Relative to Bevacizumab in Japanese Subjects
09:30 - 09:30 | Presenter: Valdimir Hanes
- Abstract
Loading... -
+
P2.04-010 - Afatinib in Combination with Pembrolizumab in Patients with Stage IIIB/IV Squamous Cell Carcinoma (SCC) of the Lung
09:30 - 09:30 | Presenter: Jonathan W Riess
- Abstract
Loading... -
+
P2.04-011 - The Using of LungCare Electromagnetic Navigated Bronchoscopy System in Lung Lesions, a New Project in China
09:30 - 09:30 | Presenter: Baohui Han
- Abstract
Loading... -
+
P2.04-012 - First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study
09:30 - 09:30 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P2.04-013 - ElevatION:NSCLC-101 – A Phase 1b Study of PDR001 Combined with Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients
09:30 - 09:30 | Author(s): Johan F. Vansteenkiste
- Abstract
Loading... -
+
P2.04-014 - Computing the Impact of Immunotherapy on NSCLC Landscape: The Advanced Non-Small Cell Lung Cancer Holistic Registry (ANCHoR)
09:30 - 09:30 | Author(s): S. Chandwani
- Abstract
Loading...
-
+
P2.05 - Early Stage NSCLC
- Type: Poster Session with Presenters Present
- Track: Early Stage NSCLC
- Presentations: 21
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.05-001 - Does CGA Impact QoL and Overall Survival in NSCLC Patients Treated with SBRT - Results of a Randomized Pilot Study
09:30 - 09:30 | Presenter: Stefan Starup Jeppesen
- Abstract
Loading... -
+
P2.05-002 - A Pilot Study on the Safety and the Efficacy of Dose Escalation in Stereotactic Body Radiotherapy for Peripheral Lung Tumor
09:30 - 09:30 | Presenter: Takamasa Mitsuyoshi
- Abstract
Loading... -
+
P2.05-003 - Stage by Stage Comparison of Radiotherapy versus Surgery in NSCLC: The Influence of Prognostic Factors on Survival Outcome
09:30 - 09:30 | Presenter: Sara Moore
- Abstract
Loading... -
+
P2.05-004 - Radiotherapy Patterns of Care for Stage I and II Non-small-cell Lung Cancer in Sydney, Australia
09:30 - 09:30 | Presenter: Andrew Duy Duc Nguyen
- Abstract
Loading... -
+
P2.05-005 - Proton Beam Therapy for Early Stage Lung Cancer: A Multi-Institutional Retrospective Study in Japan
09:30 - 09:30 | Presenter: Kayoko Ohnishi
- Abstract
Loading... -
+
P2.05-006 - Credentialing of Radiotherapy Centres in Australasia for a Phase III Clinical Trial on SABR (TROG 09.02 CHISEL)
09:30 - 09:30 | Author(s): T. Kron
- Abstract
Loading... -
+
P2.05-007 - Sterotactic-Body-Radiotherapy for Early-Lung Cancer: Is FDG-PET/TC a Predictor of Outcome?
09:30 - 09:30 | Author(s): N. Farré
- Abstract
Loading... -
+
P2.05-008 - Stereotactic Body Radiotherapy (SBRT) for Early Stage I Lung Cancer: A Review from an Oncology Center in Hong Kong
09:30 - 09:30 | Presenter: Lim Mei Ying
- Abstract
Loading... -
+
P2.05-009 - Outcome of Stereotactic Body Radiotherapy for Clinical Stage I Non Small Cell Lung Cancer and CT Findings: Comparison with Surgical Resection
09:30 - 09:30 | Presenter: Yuho Maki
- Abstract
Loading... -
+
P2.05-010 - Changes between Pre- and Post-Operative AICS (Lung) in NSCLC Patients: Predictability of High-Risk Cases with Recurrence
09:30 - 09:30 | Presenter: Masahiko Higashiyama
- Abstract
Loading... -
+
P2.05-011 - Segmentectomy versus Wedge Resection in Patients with Clinical Stage I Non-Small Cell Lung Cancer Who Were Unfit for Lobectomy
09:30 - 09:30 | Presenter: Yasuhiro Tsutani
- Abstract
Loading... -
+
P2.05-012 - Prognostic Factors for Surgically Resected Non-Small Cell Lung Cancer with Cavity Formation
09:30 - 09:30 | Presenter: Shunsuke Shigefuku
- Abstract
Loading... -
+
P2.05-013 - The Result of Preoperative Lipiodol Markings for 121 Small Pulmonary Nodules in 115 Patients
09:30 - 09:30 | Presenter: Hirofumi Suzuki
- Abstract
Loading... -
+
P2.05-014 - Factors Associated with Recovery Time to Predicted FEV1 in Non-Small-Cell Lung Cancer Patients after Lobectomy
09:30 - 09:30 | Author(s): H.W. Kim
- Abstract
Loading... -
+
P2.05-015 - Wedge Resection Is Enough for Curing GGO Patients with Minimally Invasive Adenocarcinoma (MIA) of the Lung?
09:30 - 09:30 | Presenter: Jun Zhang
- Abstract
Loading... -
+
P2.05-016 - Clinical Importance and Application of New T Descriptors in the 8th TNM Classification for Pathological T0-1 Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Masayuki Nakao
- Abstract
Loading... -
+
P2.05-017 - Prognostic Impact of the Clinical T Descriptor in the Eighth Edition of the TNM Staging System of Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Tatsuro Okamoto
- Abstract
Loading... -
+
P2.05-018 - Video-Assisted Thoracoscopic Surgery vs Thoracotomy for Early-Stage Non-Small Cell Lung Cancer: Short-Term Outcomes of a Randomized Trial
09:30 - 09:30 | Presenter: Dongrong Situ
- Abstract
Loading... -
+
P2.05-019 - Overall Survival (OS) of Pathological T1N0 Non-Small Cell Lung Cancer (NSCLC) After Resection.
09:30 - 09:30 | Presenter: Etienne Bourdages-Pageau
- Abstract
Loading... -
+
P2.05-020 - Prognostic Factors in Patients with Completely Resected Subsolid Node-Negative Lung Adenocarcinoma of 3cm or Smaller
09:30 - 09:30 | Presenter: Jung-Jyh Hung
- Abstract
Loading... -
+
P2.05-021 - Occult Nodal Metastasis Following Lobectomy for Clinical Stage I Lung Adenocarcinoma: Implications for Sublobar Resection
09:30 - 09:30 | Presenter: Yusuke Takahashi
- Abstract
Loading...
-
+
P2.06 - Epidemiology/Primary Prevention/Tobacco Control and Cessation
- Type: Poster Session with Presenters Present
- Track: Epidemiology/Primary Prevention/Tobacco Control and Cessation
- Presentations: 11
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.06-001 - Circulating Cotinine Concentrations, Self-Reported Smoking, and Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3)
09:30 - 09:30 | Presenter: Tricia L. Larose
- Abstract
Loading... -
+
P2.06-002 - Tobacco Use and Prevalence of Head and Neck Cancers among Malayali Tribes, Yelagiri Hills, Tamil Nadu, India
09:30 - 09:30 | Presenter: Delfin Lovelina Francis
- Abstract
Loading... -
+
P2.06-003 - Retrospective Study of Cerebral Thromboembolism Occurring before and after Detection of Lung Cancer (Trousseau Syndrome)
09:30 - 09:30 | Presenter: Kinnosuke Matsumoto
- Abstract
Loading... -
+
P2.06-004 - Role of Polymorphic Variants of BER and DSBR Pathway Genes in Modulating Lung Cancer Susceptibility and Prognosis of North Indian Population
09:30 - 09:30 | Presenter: Amrita Singh
- Abstract
Loading... -
+
P2.06-005 - An Exploration of Attitudes and Barriers to Uptake of Lung Cancer Screening in at Risk Adults in the United Kingdom
09:30 - 09:30 | Author(s): E.L. O'Dowd
- Abstract
Loading... -
+
P2.06-006 - Screening Values of CEA and Cyfra 21-1 for Lung Cancer in Combination with Low Dose CT (LDCT) in High-Risk Populations
09:30 - 09:30 | Presenter: Natthaya Triphuridet
- Abstract
Loading... -
+
P2.06-007 - Demographic Characteristics of Lung Cancer and Association with Wood Smoke in Mexican Population
09:30 - 09:30 | Presenter: Jeronimo Rafael Rodriguez-Cid
- Abstract
Loading... -
+
P2.06-008 - Diagnosis of Incidental Disease in Medicaid Recipients During Lung Cancer Screening
09:30 - 09:30 | Presenter: Marisa Bittoni
- Abstract
Loading... -
+
P2.06-009 - Trace Elements Affect Lung Cancer Subtypes
09:30 - 09:30 | Presenter: Ryosuke Chiba
- Abstract
Loading... -
+
P2.06-010 - Association of Vitamin D Receptor BsmI Polymorphism with Lung Cancer Risk: Evidence from a Meta-Analysis
09:30 - 09:30 | Author(s): A. Zhong
- Abstract
Loading... -
+
P2.06-011 - Assessing and Addressing Knowledge Gaps to Improve Lung Cancer Screening Rates
09:30 - 09:30 | Author(s): G. Westphal
- Abstract
Loading...
-
+
P2.07 - Immunology and Immunotherapy
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- Presentations: 65
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.07-001 - Clinicopathological Characteristics of NSCLC Patients with Nivolumab-Induced Pneumonitis
09:30 - 09:30 | Presenter: Nobuyuki Koyama
- Abstract
Loading... -
+
P2.07-002 - Drug-Related Pneumonitis in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Commercial PD-1 Inhibitors
09:30 - 09:30 | Presenter: Mizuki Nishino
- Abstract
Loading... -
+
P2.07-003 - Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Hironori Yoshida
- Abstract
Loading... -
+
P2.07-004 - Immune-Related Adverse Events (irAEs) of Nivolumab Predicts Clinical Benefit in Advanced Lung Cancer Patients
09:30 - 09:30 | Presenter: Yukihiro Toi
- Abstract
Loading... -
+
P2.07-005 - Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
09:30 - 09:30 | Author(s): C. Henon
- Abstract
Loading... -
+
P2.07-006 - Irinotecan Augmented Anti-Tumor Activity of Anti-PD-L1 through Enhancing CD8 Proliferation Regardless of Its Hematotoxicity
09:30 - 09:30 | Presenter: Toshiki Iwai
- Abstract
Loading... -
+
P2.07-007 - Retrospective Analysis of Antitumor Effects and Biomarkers of Nivolumab in NSCLC Patients with EGFR Mutations
09:30 - 09:30 | Presenter: Satoshi Watanabe
- Abstract
Loading... -
+
P2.07-008 - Does PD-L1 Expression of the Archive Surgical Specimen of Primary Tumor Predict the Sensitivity of Recurrence to Nivolumab in Patients with NSCLC?
09:30 - 09:30 | Presenter: Yuki Shiina
- Abstract
Loading... -
+
P2.07-009 - Monitoring Nivolumab Binding as a Method to Clarify the Residual Therapeutic Effects in Previously Treated Lung Cancer Patients
09:30 - 09:30 | Presenter: Akio Osa
- Abstract
Loading... -
+
P2.07-010 - Impact of Clinicopathological Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients with Previously Treated Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Tao Jiang
- Abstract
Loading... -
+
P2.07-011 - Long Follow up from Phase I Study of Nivolumab and Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
09:30 - 09:30 | Presenter: Shintaro Kanda
- Abstract
Loading... -
+
P2.07-012 - Patterns of Response to Nivolumab in Patients with Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): S. Schmid
- Abstract
Loading... -
+
P2.07-013 - Efficacy and Safety of Nivolumab in Non-Small Cell Lung Cancer with Preexisting Interstitial Lung Disease
09:30 - 09:30 | Presenter: Osamu Kanai
- Abstract
Loading... -
+
P2.07-014 - Immune Checkpoint Inhibitors for Brain Metastases of Non-Small-Cell Lung Cancer
09:30 - 09:30 | Presenter: Hironori Ashinuma
- Abstract
Loading... -
+
P2.07-015 - Reviving Chemotherapy Sensitivity after Anti-CCR4 mAb (Mogamulizumab) Treatment in Lung Cancer Patients
09:30 - 09:30 | Presenter: Koji Kurose
- Abstract
Loading... -
+
P2.07-016 - Inmunotherapy: Which Is More Important, Choosing Patients Who Will Respond or Identifying Those Who Will Die Early?
09:30 - 09:30 | Presenter: Inmaculada Ramos García
- Abstract
Loading... -
+
P2.07-017 - Association between Thyroid Dysfunction and Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Received Nivolumab
09:30 - 09:30 | Presenter: Tomoko Funazo
- Abstract
Loading... -
+
P2.07-018 - Correlation of Clinical Response and XAGE1 Immunity in Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Yoshihiro Ohue
- Abstract
Loading... -
+
P2.07-019 - Role of Anti-Angiogenesis on the Prognosis in Advanced Non-Small Cell Lung Cancer Who Are Treated with Immunotherapy
09:30 - 09:30 | Presenter: Takefumi Komiya
- Abstract
Loading... -
+
P2.07-020 - Distinct Immune Status in Patients with Adenocarcinoma and Squamous Cell Carcinoma: Implication for Immunotherapy of NSCLC
09:30 - 09:30 | Presenter: Nada Hradilova
- Abstract
Loading... -
+
P2.07-021 - A Checkpoint Molecule B7-H3 as a Novel Immune Therapy Target for Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Presenter: Kimio Yonesaka
- Abstract
Loading... -
+
P2.07-022 - Inflammatory Cytokine Induction after Anti-PD-1 Ab Administration Relates to the Efficacy and Safety in Patients with Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Yuichi Ozawa
- Abstract
Loading... -
+
P2.07-023 - Safety of Immune Checkpoint Inhibitors in Patients with Preexisting Autoimmune Disease
09:30 - 09:30 | Author(s): A. Tison
- Abstract
Loading... -
+
P2.07-024 - Real-World Data of Nivolumab for Previously Treated Non-Small Cell Lung Cancer Patients in Japan: A Multicenter Retrospective Cohort Study
09:30 - 09:30 | Presenter: Daichi Fujimoto
- Abstract
Loading... -
+
P2.07-025 - Increased Antitumor Response to Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Song Ee Park
- Abstract
Loading... -
+
P2.07-026 - Nivolumab in Non-Small Cell Lung Cancer (NSCLC): Facing the Reality
09:30 - 09:30 | Author(s): O. Merimsky
- Abstract
Loading... -
+
P2.07-027 - Efficacy and Safety of Nivolumab Therapy for Advanced NSCLC in the Expanded Access Named Patient Program in Taiwan
09:30 - 09:30 | Presenter: Bin-Chi Liao
- Abstract
Loading... -
+
P2.07-028 - Efficacy and Safety of Nivolumab in Non-Small Cell Lung Cancer Patients Who Relapse after Thoracic Radiotherapy
09:30 - 09:30 | Presenter: Teppei Yamaguchi
- Abstract
Loading... -
+
P2.07-029 - CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients
09:30 - 09:30 | Presenter: Rosalyn J. Juergens
- Abstract
Loading... -
+
P2.07-030 - Real Life Second-Line Nivolumab in Advanced Non-Small-Cell-Lung Cancer: A French Observational Multicenter Study of 259 Patients
09:30 - 09:30 | Presenter: Margaux Geier
- Abstract
Loading... -
+
P2.07-031 - Relationship between Clinical Factors and the Expression of Programmed Death Ligand 1 in Lung Cancer
09:30 - 09:30 | Presenter: Yasuhiro Kato
- Abstract
Loading... -
+
P2.07-032 - Outcomes of Nivolumab in Metastatic NSCLC Patients via the Access Program Across Multiple Tertiary Oncology Centres.
09:30 - 09:30 | Author(s): K.E. Roberts
- Abstract
Loading... -
+
P2.07-033 - Anti-PD1-Induced Rotator Cuff Injury: A Case Series
09:30 - 09:30 | Author(s): K.E. Roberts
- Abstract
Loading... -
+
P2.07-034 - Health Status in Patients with Small-Cell Lung Cancer Treated with Nivolumab Alone or Combined with Ipilimumab: CheckMate 032
09:30 - 09:30 | Author(s): A. Ardizzoni
- Abstract
Loading... -
+
P2.07-035 - Correlation Between Immune-Related Adverse Events and Efficacy in Non-Small Cell Lung Cancer Treated with Nivolumab
09:30 - 09:30 | Presenter: Koichi Sato
- Abstract
Loading... -
+
P2.07-036 - Appropriate Use of Immune Checkpoint Inhibitors in Advanced NSCLC: Effectiveness of Unique Case-Based Education on Clinical Decision-Making
09:30 - 09:30 | Presenter: Tara Herrmann
- Abstract
Loading... -
+
P2.07-037 - Developing a Predictive Clinical Outcome Model for Advanced Non-Small Cell Lung Cancer Patients
Receiving Nivolumab09:30 - 09:30 | Presenter: Wungki Park
- Abstract
Loading... -
+
P2.07-038 - Thyroid Dysfunction Arising During KEYNOTE-001 Associated with Improved Efficacy of Pembrolizumab in NSCLC Patients at UCLA
09:30 - 09:30 | Presenter: Aaron Lisberg
- Abstract
Loading... -
+
P2.07-039 - Nivolumab Experience in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC) in Toledo, Spain
09:30 - 09:30 | Author(s): E. Martinez Moreno
- Abstract
Loading... -
+
P2.07-040 - Pre-Treatment Tumor Volume in Non-Small Cell Lung Cancer (NSCLC) as a Predictor of Response to PD-1 Inhibitors
09:30 - 09:30 | Presenter: Misako Nagasaka
- Abstract
Loading... -
+
P2.07-041 - Immuno-Related Cutaneous Adverse Events (IRcutAEs) in Patients (P) with Advanced NSCLC: A Single-Institution Prospective Study
09:30 - 09:30 | Presenter: Enric Carcereny
- Abstract
Loading... -
+
P2.07-042 - Feasibility Study of Nivolumab and Docetaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Tsuneo Shimokawa
- Abstract
Loading... -
+
P2.07-043 - Efficacy and Safety of Anti-PD-1 Antibody as the First Line Treatment in Elderly Patient with Advanced Lung Squamous Cell Carcinoma: A Case Report
09:30 - 09:30 | Presenter: Hua min Shi
- Abstract
Loading... -
+
P2.07-044 - Thyroid Disfunction in Advanced NSCLC Patients Treated with Nivolumab out of Clinical Trial: A Real-World Data Analysis
09:30 - 09:30 | Presenter: Ramon Palmero
- Abstract
Loading... -
+
P2.07-045 - A Retrospective Analysis of Nivolumab-Related Pneumonitis in Non-Small Cell Lung Cancer Patients
09:30 - 09:30 | Presenter: Shuhei Tsujino
- Abstract
Loading... -
+
P2.07-046 - Nivolumab Exerts Remarkable Antitumor Activity in NSCLC After an Immune-Modulating Biochemotherapy Regimen
09:30 - 09:30 | Author(s): P. Pastina
- Abstract
Loading... -
+
P2.07-047 - Poor Performance Status and BRAF Mutation Predict Grade 3-5 Immune-Related Adverse Events in Pts with Advanced NSCLC
09:30 - 09:30 | Presenter: Yan Wang
- Abstract
Loading... -
+
P2.07-048 - Immunotherapy vs. Targeted Therapy - Who Wins? A Case Series
09:30 - 09:30 | Presenter: Inbar Finkel
- Abstract
Loading... -
+
P2.07-049 - Early Clinical Predictors of Progressive Disease or Non-Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): R. Kumar
- Abstract
Loading... -
+
P2.07-050 - Impact of Steroid Use for Immune Related Adverse Events on Outcomes in Non-Small Cell Lung Cancer (NSCLC) Treated with Checkpoint Inhibitors
09:30 - 09:30 | Presenter: Neil J Shah
- Abstract
Loading... -
+
P2.07-051 - Immune Checkpoint Associated Cardiotoxicity: An Update
09:30 - 09:30 | Author(s): A. Chauhan
- Abstract
Loading... -
+
P2.07-052 - Detection of KRAS Mutation in Blood Predicts Favorable Response to Immunotherapy in NSCLC
09:30 - 09:30 | Presenter: Martin Frederik Dietrich
- Abstract
Loading... -
+
P2.07-053 - A Case of Small Cell Lung Cancer Complicated During Nivolumab Administration as Second Line Treatment for Squamous Cell Lung Cancer
09:30 - 09:30 | Presenter: Tomoki Kimura
- Abstract
Loading... -
+
P2.07-054 - Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): M. Georgieva
- Abstract
Loading... -
+
P2.07-055 - Indirect Comparison between Immune-Checkpoint Inhibitors for 2nd Line Non-Small Cell Lung Cancer – a Network Meta-Analysis
09:30 - 09:30 | Author(s): P. Tan
- Abstract
Loading... -
+
P2.07-056 - SAKK 16/14 – Perioperative Anti-PD-L1 Antibody Durvalumab in Patients with Stage IIIA(N2) Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Presenter: Sacha I Rothschild
- Abstract
Loading... -
+
P2.07-057 - Anti-PD-1/PD-L1 Antibodies Combine with Chemotherapy or CTLA4 Antibodies for First-Line Treatment of Advanced Lung Cancer
09:30 - 09:30 | Presenter: Yun Fan
- Abstract
Loading... -
+
P2.07-058 - First-In-Human Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, for Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Julie R Brahmer
- Abstract
Loading... -
+
P2.07-059 - Phase I Trial of Gene Mediated Cytotoxic Immunotherapy (GMCI) for Malignant Pleural Effusion (MPE) and Malignant Pleural Mesothelioma (MPM)
09:30 - 09:30 | Presenter: Daniel H. Sterman
- Abstract
Loading... -
+
P2.07-060 - Response Assessment and Subgroups Analysis According to the Lung Immune Prognostic Index (LIPI) for Immunotherapy in Advanced NSCLC Patients
09:30 - 09:30 | Presenter: Laura Mezquita
- Abstract
Loading... -
+
P2.07-061 - Nivolumab for Patients with Non-Small Cell Lung Carcinoma in Patients with Progression to One or More Lines of Chemotherapy in Mexican Population
09:30 - 09:30 | Presenter: Jeronimo Rafael Rodriguez-Cid
- Abstract
Loading... -
+
P2.07-062 - PIVOT-02: Phase 1/2 Study of NKTR‐214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies
09:30 - 09:30 | Presenter: Vassiliki A Papadimitrakopoulou
- Abstract
Loading... -
+
P2.07-062a - Single Institutional Experience of the Use of PD-1 Inhibitors to Non-Small Cell Lung Cancer Patients with Preexisting Autoimmune Diseases
09:30 - 09:30 | Presenter: Mehmet Altan
- Abstract
Loading... -
+
P2.07-062b - DNA Damage Repair Targeting Upregulates PD-L1 Level and Potentiates the Effect of PD-L1 Blockade in Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Triparna Sen
- Abstract
No abstract available for this presentation
-
+
P2.07-062c - A Phase II Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Lung Adenocarcinoma
09:30 - 09:30 | Author(s): K. Wnuk-Lipinska
- Abstract
No abstract available for this presentation
-
+
P2.08 - Locally Advanced Nsclc
- Type: Poster Session with Presenters Present
- Track: Locally Advanced NSCLC
- Presentations: 7
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.08-001 - Hand Grip Strength Is an Independent Prognostic Factor for Mortality in Patients with NSCLC Undergoing Radiotherapy
09:30 - 09:30 | Author(s): Chris Burtin
- Abstract
Loading... -
+
P2.08-002 - A Nomogram for Predicting Underlying Beneficiaries for Resectable IIIA/N2 NSCLC Patients
09:30 - 09:30 | Presenter: Chao Zhang
- Abstract
Loading... -
+
P2.08-003 - An Audit of Concurrent Chemoradiotherapy for Non-Small Cell Lung Cancer at the Leeds Cancer Centre (LCC)
09:30 - 09:30 | Author(s): F. Sun
- Abstract
Loading... -
+
P2.08-004 - Pathologic Complete Response as an Independed Prognostic Factor in Patients with Locally Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Waldemar Schreiner
- Abstract
Loading... -
+
P2.08-005 - Salvage Lung Surgery Following Definitive Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Waldemar Schreiner
- Abstract
Loading... -
+
P2.08-006 - Immunological Biomarkers Characterization in Locally Advanced Non-Small Cell Lung Cancer Treated with Concurrent Chemo-Radiotherapy
09:30 - 09:30 | Author(s): M. Saigi
- Abstract
Loading... -
+
P2.08-007 - Five-Year Results of Concurrent Chemotherapy and Isotoxic Radiotherapy Dose-Escalation with IMRT in Stage III NSCLC (NCT01166204)
09:30 - 09:30 | Presenter: Dirk K De Ruysscher
- Abstract
Loading...
-
+
P2.09 - Mesothelioma
- Type: Poster Session with Presenters Present
- Track: Mesothelioma
- Presentations: 10
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.09-001 - Effects of Tumor Burden Reduction on Survival in Epithelioid Pleural Mesothelioma
09:30 - 09:30 | Presenter: Aaron S. Mansfield
- Abstract
Loading... -
+
P2.09-001a - TNM or Tumor Volume for Predicting Prognosis in Malignant Pleural Mesothelioma: Still an Open Debate
09:30 - 09:30 | Author(s): M. Imbimbo
- Abstract
Loading... -
+
P2.09-002 - Prevalence and Survival of Malignant Pleural Mesothelioma Patients Treated in a Single Brazilian Cancer Center
09:30 - 09:30 | Author(s): João Navarro Reolon
- Abstract
Loading... -
+
P2.09-003 - Dissecting the Immune Environment in Malignant Pleural Mesothelioma: Results from a Prospective Assessment
09:30 - 09:30 | Author(s): C. Riganti
- Abstract
Loading... -
+
P2.09-004 - PD-L1 Protein Expression Is Negative Prognostic Factor in Malignant Pleural Mesothelioma in Central Europe
09:30 - 09:30 | Presenter: Luka Brcic
- Abstract
Loading... -
+
P2.09-005 - The C-reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma
09:30 - 09:30 | Presenter: Shinkichi Takamori
- Abstract
Loading... -
+
P2.09-005a - Clinical Characteristics of Early Stage, Malignant Pleural Mesothelioma
09:30 - 09:30 | Author(s): Yoshiki Negi
- Abstract
Loading... -
+
P2.09-006 - FISH Analysis of p16 and BAP1 Immunohistochemistry for the Diagnosis of Mesothelioma
09:30 - 09:30 | Presenter: Kenzo Hiroshima
- Abstract
Loading... -
+
P2.09-007 - Pleural Biopsy in Patients Suspected of Malignant Pleural Mesothelioma Consecutive 377 Cases
09:30 - 09:30 | Presenter: Masaki Hashimoto
- Abstract
Loading... -
+
P2.09-008 - Usefulness of Immunohistochemistry in the Differential Diagnosis of Epithelioid Mesothelioma and Lung Squamous Cell Carcinoma
09:30 - 09:30 | Presenter: Kei Kushitani
- Abstract
Loading...
-
+
P2.10 - Nursing/Palliative Care/Ethics
- Type: Poster Session with Presenters Present
- Track: Nursing/Palliative Care/Ethics
- Presentations: 7
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.10-001 - Factors Associated with Quality of Life among Patients with Lung Cancer
09:30 - 09:30 | Presenter: Yi-Lin Wu
- Abstract
Loading... -
+
P2.10-002 - A Study on the Relation between Gender and Quality of Life for Lung Cancer Patients
09:30 - 09:30 | Presenter: Yi-Lin Wu
- Abstract
Loading... -
+
P2.10-003 - The Deterioration and Prognostic Value of Functional Capacity in Patients with Lung Cancer: A Systematic Review
09:30 - 09:30 | Presenter: Laerke Winther
- Abstract
Loading... -
+
P2.10-004 - Efficacy and Safety of Viscum Album (Helixor M) to Treat Malignant Pleural Effusion in Patients with Advanced Lung Cancer
09:30 - 09:30 | Presenter: Yun-Gyoo Lee
- Abstract
Loading... -
+
P2.10-005 - Overall Survival of Lung Cancer Patients with Brain Metastases in a Developing Country
09:30 - 09:30 | Presenter: Tomi Kovacevic
- Abstract
Loading... -
+
P2.10-006 - Prognostic Factors of Mortality and Recurrence of Malignant Pleural Effusion in High-Risk Tumors According to the LENT Score Study
09:30 - 09:30 | Presenter: Fernando Conrado Abrão
- Abstract
Loading... -
+
P2.10-007 - Quality of Life across Various Treatment Lines in Metastatic Lung Cancer Patients
09:30 - 09:30 | Presenter: Aseem Rai Bhatnagar
- Abstract
Loading...
-
+
P2.11 - Patient Advocacy
- Type: Poster Session with Presenters Present
- Track: Patient Advocacy
- Presentations: 2
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.11-001 - Evaluation of a Cultural Notebook of Self-Expression and Follow-Up Among Patients with Lung Cancer in French Polynesia
09:30 - 09:30 | Presenter: Eric Parrat
- Abstract
Loading... -
+
P2.11-002 - To Live and Work with Lung Cancer: Coping Strategies of a Stage 4 Patient
09:30 - 09:30 | Presenter: Satoko Kono
- Abstract
Loading...
first
prev
